ONC BeOne Medicines Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1651308 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY32.9%
TTM net income YoY1,235.6%
TTM EPS YoY1,400.0%
Revenue 3-yr CAGR44.2%
Net income 3-yr CAGR—
Margins
Gross margin89.4%
Operating margin17.8%
Net margin13.9%
FCF margin21.9%
EBITDA margin20.2%
Returns
ROE18.4%
ROA10.5%
ROIC (approx.)158.2%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets41.1%
Debt / equity0.18x
Current ratio3.55x
Interest coverage8.31x
Cash quality & payout
Operating cash flow / net income1.74x
Accruals ratio-7.7%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B |
| Cost of revenue | — | — | — | $286.48M | $164.91M |
| Gross profit | $4.67B | $3.22B | $2.08B | $1.13B | $1.01B |
| R&D expense | $2.15B | $1.95B | $1.78B | $1.64B | $1.46B |
| SG&A expense | $2.08B | $1.83B | $1.51B | $1.28B | $990.12M |
| Operating income | $447.14M | -$568.20M | -$1.21B | -$1.79B | -$1.44B |
| Interest expense | $58.23M | $21.80M | $4.36M | $21.70M | $29.26M |
| Pretax income | $416.85M | -$533.00M | -$825.84M | -$1.96B | -$1.44B |
| Income tax | $129.92M | $111.78M | $55.87M | $42.78M | $19.23M |
| Net income | $286.93M | -$644.79M | -$881.71M | -$2.00B | -$1.46B |
| EBITDA | $588.82M | -$396.44M | -$1.12B | -$1.72B | -$1.39B |
| EPS (basic) | 0.20 | -0.47 | -0.65 | -1.49 | -1.21 |
| EPS (diluted) | 0.19 | -0.47 | -0.65 | -1.49 | -1.21 |
| Weighted avg. shares (diluted) | 1.47B | 1.37B | 1.36B | 1.34B | 1.21B |
| Banking | |||||
| Net interest income | — | — | $74.01M | $52.48M | -$15.76M |
| Balance sheet | |||||
| Cash & equivalents | $4.55B | $2.64B | $3.17B | $3.88B | $4.38B |
| Short-term investments | — | — | $2.60M | $665.25M | $2.24B |
| Receivables | $865.08M | $676.28M | $358.03M | $173.17M | $483.11M |
| Inventory | $608.23M | $494.99M | $416.12M | $282.35M | $242.63M |
| Current assets | $6.23B | $3.99B | $4.20B | $5.21B | $7.61B |
| PP&E, net | $1.64B | $1.58B | $1.32B | $845.95M | $587.61M |
| Goodwill | — | — | — | $109,000 | $109,000 |
| Intangibles | $62.70M | $51.09M | $57.14M | $40.62M | $46.68M |
| Total assets | $8.19B | $5.92B | $5.81B | $6.38B | $8.54B |
| Current liabilities | $1.83B | $2.21B | $1.81B | $1.47B | $1.60B |
| Short-term debt | $57.29M | $851.53M | $688.37M | $328.97M | $427.56M |
| Long-term debt | $961.91M | $166.48M | $197.62M | $209.15M | $202.11M |
| Total debt | $1.02B | $1.02B | $885.98M | $538.12M | $629.68M |
| Total liabilities | $3.83B | $2.59B | $2.27B | $2.00B | $2.40B |
| Shareholders' equity | $4.36B | $3.33B | $3.54B | $4.38B | $6.13B |
| Net debt | -$3.53B | -$1.62B | -$2.29B | -$3.34B | -$3.75B |
| Shares outstanding | 1.44B | 1.39B | 1.36B | 1.36B | 1.33B |
| Cash flow statement | |||||
| Operating cash flow | $1.13B | -$140.63M | -$1.16B | -$1.50B | -$1.30B |
| Capital expenditure | $185.84M | $492.66M | $561.90M | $325.43M | $262.94M |
| Free cash flow | $941.74M | -$633.29M | -$1.72B | -$1.82B | -$1.56B |
| Investing cash flow | -$276.15M | -$548.35M | $60.00M | $1.08B | $640.66M |
| Financing cash flow | $1.06B | $193.45M | $416.48M | -$18.97M | $3.64B |
| Depreciation & amortization | $141.69M | $171.76M | $87.67M | $66.28M | $46.46M |
| Stock-based compensation | $510.86M | $441.62M | $367.62M | $303.16M | $240.71M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.